Information Provided By:
Fly News Breaks for September 5, 2017
LGND
Sep 5, 2017 | 09:27 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals to $157 following after the company announced Phase 2 data from its LGD-6972 study in type 2 diabetes mellitus. The analyst this morning assumed coverage of the shares. Statistically significant reductions in HbA1c at all doses tested were reported and potential partners should like the safety as well, Pantginis tells investors in a research note. The analyst projects a global partnership and a 25% royalty for the drug.
News For LGND From the Last 2 Days
There are no results for your query LGND